| 1.1 0.04 (3.77%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.41 |
1-year : | 1.65 |
| Resists | First : | 1.21 |
Second : | 1.41 |
| Pivot price | 1.06 |
|||
| Supports | First : | 1.08 |
Second : | 1 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.07  |
| MA(100) : | 1.14 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 54.7 |
D(3) : | 41.5 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 1.54 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANTX ] has closed below upper band by 6.7%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Mon, 23 Feb 2026
AN2 Therapeutics (ANTX) CDO receives new stock options and RSU grants - Stock Titan
Mon, 23 Feb 2026
Director granted 20,400 stock options at AN2 Therapeutics (ANTX) - Stock Titan
Mon, 23 Feb 2026
ANTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fri, 30 Jan 2026
AN2 Therapeutics adjusts leadership roles and executive compensation - The Globe and Mail
Fri, 09 Jan 2026
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 25.4 (%) |
| Held by Institutions | 40.7 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 45 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.99 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|